Research Peptide Customs Seizure Guide: Outcomes, Notices and Risk Reduction

For personal-use research peptide orders, customs seizure in the United States, United Kingdom, Canada, and most of the European Union almost always ends one way: the package is destroyed, the buyer receives a letter (sometimes), and no criminal charges follow. Operation Pangea XVII — the December 2024–May 2025 Interpol-coordinated bust that produced 769 arrests across 90 countries — targeted criminal syndicates importing 50.4 million doses worth $65 million, not personal-use buyers. The headlines and the lived reality are two different things, and this guide explains the gap.

The article walks through what a customs seizure legally is, what the US and other jurisdictions actually do with personal-use peptide shipments, how to read a seizure notice if you've received one, whether your address gets flagged, what reduces seizure risk before you order, and where the line sits between routine destruction and criminal prosecution. For broader regulatory context, see peptide legality by country and the FDA peptide regulation timeline. For shipping logistics that come before the seizure question, see peptide shipping, cold chain and customs delivery.

Peptigrity is an independent peptide review platform — it does not sell peptides and does not take affiliate commissions from any vendor. That independence is what allows this article to describe the real outcomes; vendor-run guides cannot honestly tell you "the worst case is destruction" because that undercuts their own cold-chain shipping pitch.

What does "seized by customs" actually mean?

"Customs seizure" describes a specific legal action: a customs agency takes physical custody of a package, issues a written notice to the importer, and initiates a forfeiture process under domestic law. It is distinct from a customs hold (a temporary delay for inspection or documentation), an import refusal (where the package is returned to sender), and an abandonment (where the importer chooses not to claim the package). Each of the four outcomes has different paperwork, different timelines, and different consequences for the buyer — and conflating them is where most online confusion starts.

A seizure means the package has left the postal system and entered the customs agency's evidence chain. It is not "stuck somewhere" or "waiting for clearance." Once a notice is issued, the buyer typically has a fixed window to respond — 35 days under the US Civil Asset Forfeiture Reform Act (CAFRA) — and silence in that window leads to forfeiture and destruction by default. A seizure also does not, by itself, indicate that a criminal investigation has been opened. For unscheduled research peptides at personal-use quantities, the documented pattern is administrative forfeiture only.

Seizure vs hold vs refusal vs abandonment — the four customs outcomes

The word "seized" gets used loosely on Reddit and forums. A package that was held for three days and then delivered was not seized. A package that was refused and returned to sender was not seized. Seizure specifically means custody-plus-notice — and only seizure carries the destruction-by-default outcome.

Why peptides specifically get flagged at customs

Several characteristics push research peptide shipments above customs algorithmic thresholds. Unlabelled vials containing fine white powder match the visual signature customs officers are trained to flag. Vendor country of origin matters — shipments from China, India, and certain Eastern European jurisdictions face higher inspection rates than intra-EU or domestic shipments. Customs declaration accuracy matters too: a declaration of "research sample" with low declared value attracts less scrutiny than "pharmaceutical product" with a $400 declared value. Prior seizure history at the destination address raises the inspection probability for subsequent packages, though not infinitely. And shipment volume — a single small package looks different from a parcel with 40+ vials, which matches the profile of a commercial-scale import.

For practical guidance on the shipping side of this — packaging, declared value, carrier choice — see peptide shipping, cold chain and customs delivery.

What actually happens if customs seizes your peptides in the United States?

For a personal-use research peptide shipment intercepted in the US, the practical outcome is destruction of the package and a written notice to the addressee — usually citing 19 USC 1595a(c)(2)(A) (forfeiture of merchandise introduced contrary to law) and 21 USC 331 (the Food, Drug, and Cosmetic Act prohibition on introducing unapproved new drugs into commerce). Criminal charges for personal-use quantities of unscheduled research peptides are extremely rare. The buyer typically has 35 days under CAFRA to respond; the most common response is no response, which leads to administrative forfeiture and destruction.

The two statutes work together. 21 USC 331 defines the prohibited acts under the Food, Drug, and Cosmetic Act — most personal-use research peptides qualify as "unapproved new drugs" because they are not FDA-approved for human use. 19 USC 1595a(c)(2)(A) then gives Customs and Border Protection (CBP) the authority to seize merchandise that has been "introduced or attempted to be introduced into the United States contrary to law." When a Notice of FDA Action cites both, it means: the FDA classifies this package as an unapproved drug; CBP has accordingly taken custody. For independent peptide-specific legal commentary on this framework, see the Holt Law deep dive on the regulatory status of compounded peptides.

The Notice of FDA Action — what it says and what it doesn't

A US Notice of FDA Action is a structured one-page document issued by the FDA's import operations division, often co-branded with CBP. It identifies the seized merchandise, cites the statutory basis (typically 21 USC 331 plus 19 USC 1595a), states the date of seizure, and gives the importer 35 days under CAFRA to file a petition or claim. It does not, by itself, indicate that a criminal investigation has been opened. It does not reference the FBI, the DEA, or local law enforcement. And it does not trigger any obligation on the buyer to respond — silence is a valid choice and is, in practice, the most common one.

The notice is sent by certified mail to the address on the package. Buyers who use a shipping address that is not their primary residence (a UPS Store box, for example) will still receive the notice — the certified-mail tracking will reach them. The notice includes a case number, an issuing officer's address, and a checklist called the Election of Proceedings form that the buyer either returns or doesn't.

Your three options after a seizure notice (and what most people choose)

Three options exist under CAFRA. Each has documented outcomes for personal-use research peptide cases:

1. File a petition for relief. Submitted on CBP Form 4609, the petition asks the agency to mitigate or cancel the forfeiture. Petitions for unapproved peptides almost never succeed — the underlying statutory violation (introducing an unapproved drug) is not curable by mitigation. Petitions also create a written record that the importer was aware the merchandise was unapproved, which has implications if seizures repeat.

2. File a claim and force the case to court. Filing a claim triggers a federal civil forfeiture lawsuit. The government must then prove the merchandise is forfeitable; the importer can contest. Costs run into the thousands of dollars in attorney fees, success rates for unapproved peptide cases are low, and the lawsuit becomes part of the public record. Reserved for exceptional circumstances — typically high-value shipments, prescription medications confused for research peptides, or repeat-seizure situations where the importer's profile demands a defense.

3. Do nothing. The 35-day clock runs out, the merchandise is administratively forfeited under 19 USC 1595a, and the package is destroyed. No further action follows in the overwhelming majority of personal-use cases. This is what attorneys advising peptide buyers most commonly recommend, and it is what documented buyer-experience patterns confirm is the routine outcome.

For most personal-use peptide buyers in the US, option 3 is the de facto result — either by deliberate choice or by default.

Will your address be flagged for future orders?

A first seizure adds the recipient address to administrative records at CBP and the relevant FDA import office, but does not automatically flag every future package to that address. CBP's risk-targeting system weights prior seizures as one input among many, alongside vendor origin, declared contents, shipment value, and carrier patterns. In practice, repeat seizures from the same source — same vendor, same country, similar packaging — produce ongoing scrutiny; isolated single seizures rarely do. Buyers commonly report that switching vendors, changing the source country, and reducing order frequency restore previous interception rates within 6–12 months.

When a US peptide import case actually goes criminal

US peptide seizures escalate to criminal charges when one or more of the following indicators is present: commercial-scale quantities (hundreds of vials, multi-consignment patterns), evidence of resale (shipping addresses matching wholesale buyers, payment trails, online listings), importation of compounds with their own criminal statute (HGH under 21 USC 333(f) is the textbook case — the Anti-Drug Abuse Act of 1988 explicitly criminalizes HGH possession and distribution outside legitimate medical use), or importation of scheduled controlled substances mistakenly classified by the buyer as peptides. For unscheduled research peptides at personal quantities, criminal prosecution is documented as exceptional, not routine. The newsworthy cases — Operation Pangea XVII, the syndicate-scale prosecutions reported across multiple jurisdictions in 2025 and 2026 — uniformly involve commercial indicators, not single personal orders.

For broader regulatory context on which compounds carry which classifications, see the FDA peptide regulation timeline. The Cat 1/2 status of individual peptides changes frequently — as of April 2026, HHS Secretary Kennedy had directed the FDA to remove 12 peptides from Category 2 status pending the July 2026 PCAC review; verify the current FDA Bulk Drug Substances list before relying on this article's classifications.

What about the UK, EU, Canada, and Australia?

Outside the United States, customs outcomes for personal-use peptide imports range from routine destruction with no further action (UK, Canada, intra-EU shipments) to destruction plus regulatory follow-up (Germany, Australia for non-trivial quantities) to genuine criminal prosecution risk (Singapore, Japan, certain Gulf states). The main variables are whether the country treats research peptides as unscheduled chemicals or as prescription-only medicines, and whether the customs agency works jointly with a health regulator that pursues importers separately. Every claim below is current as of April 2026 and writers should verify against the linked regulators before relying on the table for any specific decision.

The intra-EU shipping shortcut

Packages that move between EU member states do not face customs at all under the EU single market. A buyer in Germany ordering from a Slovakia-based or Spain-based vendor receives the parcel through normal postal delivery, with no border inspection, no import declaration, and no duty assessment. This is why EU-based peptide vendors heavily emphasize phrases like "ships from Europe" and "no customs delays" in their marketing — for EU customers, those vendors genuinely eliminate seizure risk. The advantage disappears when the package's origin is non-EU: a US buyer ordering from a Slovakia-based vendor still goes through US customs on arrival, and a UK buyer (post-Brexit) ordering from any EU vendor goes through UK Border Force.

Why Australia is stricter than the US

Australia treats personal-use peptide imports more aggressively than the United States, in part because the Australian Border Force (ABF) and the Therapeutic Goods Administration (TGA) operate jointly. Most research peptides fall under Schedule 4 of the Poisons Standard, requiring a prescription. The April 2026 Victorian case — where ABF intercepted 640 vials of performance and image-enhancing drugs across multiple air cargo consignments, identified an additional 76 consignments to the same recipient since April 2025, and arrested three people on charges of importing $2 million worth of substances — illustrates how the joint enforcement model works against syndicate-scale operations. Personal-use single-shipment seizures in Australia still typically end in destruction plus a TGA notice, but the threshold for joint ABF/TGA escalation is materially lower than the US equivalent. The TGA's press release on the Victoria case documents the operational pattern.

The countries where buyers should genuinely worry

Three jurisdictions sit in a different category altogether: Singapore, the United Arab Emirates, and Japan to a lesser extent. Singapore's Health Products Act and Misuse of Drugs Act framework treats unauthorized pharmaceutical imports — including research peptides — as prosecutable offenses, with documented cases of personal-use buyers facing charges. The UAE applies similar strictness. Japan permits a limited personal-import allowance for some compounds but applies the Pharmaceutical Affairs Law strictly to others. For buyers in these jurisdictions, the destruction-as-default reality described elsewhere in this article does not apply — the realistic worst case is criminal charges, not just a destruction notice. The Interpol Operation Pangea XVII communiqué documents the global enforcement pattern across all three categories.

How to read a customs seizure notice (US-focused)

A US Notice of FDA Action or CBP Notice of Seizure is a structured single-page document with a fixed set of fields: the case number, the seized merchandise description, the statutory basis, the date of seizure, the declared value, the importer's three options, and a deadline (35 days under CAFRA). Each field has a specific meaning that determines what to do next. Buyers who read the notice carefully can usually decide their response in under 15 minutes — most decisions are simpler than the legalese suggests.

The single most useful diagnostic on the notice is the statutory basis. A notice citing 19 USC 1595a + 21 USC 331 is a routine unapproved-drug administrative case. A notice citing 21 USC 333(f) (HGH) or any controlled-substance statute is materially different and warrants attorney consultation. A notice mentioning criminal investigation, indictment, or grand jury reference is different again — these phrases should never appear on a routine seizure notice for unscheduled research peptides.

The 35-day clock — what happens at day 0, day 35, and day 36

The clock starts on the date printed on the notice (or the date of receipt under certain mailing rules — verify on the form itself). At day 35, the response window closes. At day 36, if no petition or claim has been filed, CBP processes the seizure as administrative forfeiture under CAFRA — the merchandise is forfeited to the government, transferred to the FDA's destruction queue, and destroyed. The destruction is logged in the case record but does not generate further notification to the importer. The case is closed.

When (if ever) you should file a petition for relief

Petitions for relief have low success rates for unapproved peptide seizures because the underlying statutory violation — introducing an unapproved drug into commerce — is not mitigable. A petition makes sense in narrow circumstances: the package was misidentified (it actually contained an FDA-approved prescription medication for which you have a prescription); the package was a return/replacement of a previously legal shipment; or you intend to use the petition record to support a future claim or court challenge. For ordinary research peptide seizures, attorneys generally advise against filing — it creates a written record that you knew the merchandise was unapproved.

When you should consult a customs attorney

Three situations warrant attorney consultation. Quantity above personal-use threshold (rough working benchmark: 50+ vials in one shipment, or repeat shipments aggregating to similar volumes). Compounds with their own criminal statute — HGH most importantly, anabolic steroids in some classifications, and any controlled substance. Repeat seizures — by the third seizure to the same address, a customs attorney can advise on whether the pattern is approaching commercial-intent territory. Flat-fee consultations with customs/administrative-law attorneys typically cost $200–$500. For the underlying trust-score methodology Peptigrity uses to evaluate vendors — including their reship policies, which become relevant after a seizure — see the methodology article.

Will future orders be flagged after a seizure?

A first customs seizure adds the recipient address to administrative records at CBP and the relevant FDA import office, but does not automatically flag every future package to that address. CBP's risk-targeting weights prior seizures alongside vendor origin, declared contents, shipment value, packaging, and carrier patterns. In practice, repeat seizures from the same source (same vendor, same country, same packaging) increase the chance of further interceptions; isolated single seizures rarely produce ongoing scrutiny. Documented buyer-experience patterns suggest that switching vendors, changing source country, and reducing order frequency typically restore baseline interception rates within 6–12 months.

What changes after the second seizure

A second seizure to the same address noticeably elevates the inspection rate for incoming packages from peptide-relevant origins. CBP's risk algorithms weight repeat patterns more heavily than single events. Buyers who experience two seizures in close succession from the same vendor commonly report that subsequent shipments from that vendor are intercepted at substantially higher rates — sometimes effectively 100% — while shipments from a different vendor in a different country pass through normally. The flag is vendor-pattern-specific more than address-specific.

What changes after the third seizure

A third seizure shifts the analytical question from "is this a careless personal-use buyer?" to "is this consistent with a commercial-intent pattern?" At this threshold, FDA Office of Criminal Investigations (FDA-OCI) referral becomes a real possibility — not certain, but a defensible administrative escalation if the quantities or frequency suggest resale. The "personal use" framing also begins to erode: a buyer who has knowingly attempted to import unapproved drugs three times has a harder time arguing innocent intent than one who has done so once. This is the threshold at which buyers should stop and reconsider their approach, and at which attorney consultation genuinely becomes useful.

What you can do to reduce flagging risk going forward

Three buyer-side decisions reduce repeat-seizure risk meaningfully: switch to a vendor with a domestic presence in your jurisdiction (eliminating customs entirely); space orders out by months rather than weeks; and reduce single-shipment quantity. For practical vendor evaluation, see Peptigrity's buyer's checklist for evaluating peptide shops and how to spot a scam peptide shop. Vendor selection drives the seizure-risk equation more than any other variable — a domestic vendor with a transparent reship policy reduces the realistic seizure-cost exposure to near zero.

How to reduce the chance your order gets seized in the first place

Three buyer-side decisions reduce seizure risk meaningfully: vendor location (a domestic vendor in your country avoids customs entirely), vendor reship policy (some vendors guarantee a free reship if customs intercepts a package, transferring the financial risk to them), and order size and frequency (single small orders attract less algorithmic flagging than large or rapid-repeat shipments). None of these eliminates risk in cross-border scenarios, but together they shift the realistic expected outcome from "one in three packages seized" toward "rare or never."

Vendor location matters more than the peptide itself

The single largest seizure-risk variable is whether the package crosses an international border. Domestic shipping — US-to-US, UK-to-UK, Australia-to-Australia — involves zero customs interaction. Intra-EU shipping is the same: under EU free movement rules, a parcel from Slovakia to Germany passes through normal post with no border inspection. Cross-border shipments face progressively higher risk depending on origin–destination pair, with China-to-Western and Eastern-Europe-to-North-America being the highest-flagged corridors. Buyers in countries with developed domestic vendor markets (US, UK, Germany, Australia) can almost always find a domestic option for the major research peptides; buyers in markets without domestic supply face an unavoidable customs interaction.

Reship policies — what vendors actually offer

Reship policies vary significantly by vendor. The three common patterns are: guaranteed free reship on customs seizure with proof of seizure notice (the buyer-friendly model — the vendor absorbs the loss), 50/50 split where the vendor reships at half price, and no reship where the seizure is the buyer's loss in full. Some vendors require photographic evidence of the seizure notice; others accept a tracking-system status of "seized" or "destroyed" as sufficient proof. Reship policies are listed on the vendor's terms-of-service page and are tracked in Peptigrity's shop directory where the policy has been verified. Reship terms are one of the cheapest insurance mechanisms a peptide buyer has — confirm before placing an order, not after.

How packaging choices affect seizure rate

Several packaging variables affect inspection probability. Declared value: a low declared value ($20–$50 for a "research sample") attracts less commercial-import scrutiny than a $400 declared value with a "pharmaceutical product" description. Declared contents: "research chemical sample" or specific neutral phrasing is less inspection-attracting than "peptide" or named compound. Carrier choice: courier-dispatched packages (DHL, FedEx, UPS) face systematic customs processing; standard postal mail (USPS, Royal Mail, Deutsche Post) faces probabilistic inspection. Packaging visibility: opaque mailers attract less attention than transparent or padded envelopes that reveal vial shapes. None of these changes the underlying legal status — a misdeclared peptide shipment is still subject to seizure on inspection — but they shift the probability of triggering inspection in the first place.

Buyer-side seizure-risk reduction checklist

When customs seizures actually become criminal cases

Criminal prosecution following a customs peptide seizure is the exception, not the rule, and it tracks closely with commercial-scale indicators: large quantities, multiple consignments to the same address, evidence of resale, or compounds that carry their own criminal statute (HGH in the US under 21 USC 333(f); anabolic steroids; controlled compounds). For ordinary personal-use research peptide buyers in Western jurisdictions, the documented enforcement pattern is overwhelmingly destruction-only — no criminal referral, no prosecution, no court appearance.

The newsworthy cases of 2025–2026 illustrate the threshold clearly. Operation Pangea XVII reported 769 arrests across 90 countries between December 2024 and May 2025, with $65 million in illicit pharmaceuticals seized and 13,000 websites/social-media accounts taken down — but every documented arrest involved either trafficking-scale quantities or counterfeit pharmaceutical operations, not personal-use single orders. The April 2026 Australian case involved 640 intercepted vials in a single batch and 76 prior consignments to the same recipient over an eight-month period — quantities and frequency that no honest reader would mistake for personal use.

The April 2026 ABF/TGA Victoria case — what it shows and what it doesn't

The April 2026 case is the cleanest recent example of the criminal threshold. Three Victorians were charged after the Australian Border Force, the Therapeutic Goods Administration, and Victoria Police completed an eight-month joint investigation. ABF officers had intercepted 640 vials of performance and image-enhancing drugs across multiple air cargo consignments starting in August 2025, and follow-up investigation identified 76 prior consignments to the same recipient since April 2025. The TGA's press release on the Victoria case describes "an alleged criminal syndicate" — language that is materially different from how a personal-use seizure would be characterized. The estimated street value was over $2 million.

The case demonstrates two things. First, the threshold for criminal escalation in Australia is high — eight months of investigation, hundreds of intercepted vials, and 76 separate consignments preceded the arrests. Second, the joint ABF/TGA enforcement model is operationally active in Australia in a way that is uncommon in the US for unscheduled research peptides. Personal-use single-shipment buyers in Australia still face destruction-only outcomes, but the Australian framework is structurally more capable of escalation than the US equivalent.

Why HGH is treated differently than research peptides in the US

Human growth hormone (HGH) sits in a different US legal category than the typical research peptide. Under 21 USC 333(f), enacted as part of the Anti-Drug Abuse Act of 1988, HGH possession or distribution outside legitimate medical use is a federal criminal offense — not an FD&C Act administrative violation. A customs seizure of HGH carries materially higher legal exposure than a seizure of BPC-157 or TB-500, even at the same quantity. The same statutory framework applies to anabolic steroids under 21 USC 802 (controlled substances). Buyers should not generalize the "destruction-only" outcome described elsewhere in this article to HGH or anabolic-steroid imports — those are different cases entirely, and attorney consultation is genuinely warranted from the first seizure forward.

The signals that turn a routine seizure into a criminal investigation

Five signals push a customs case toward criminal investigation: quantity scaling beyond plausible personal use; repeat seizures to the same address forming a documented pattern; resale evidence (online listings, payment trails to wholesale buyers, business addresses); importation of compounds with their own criminal statutes (HGH, anabolic steroids, controlled substances); and importation alongside other prohibited items that triggers a broader investigation (illicit substances bundled in the same shipment). For unscheduled research peptides at personal quantities, none of these signals are present in a typical seizure — which is why the routine outcome is administrative forfeiture and destruction. For broader context on how the regulatory landscape is moving, see Peptigrity's state of the peptide industry summary.

Frequently Asked Questions

Will I get a letter if customs seizes my peptides?

In the US, almost always — the FDA issues a Notice of FDA Action via certified mail to the address on the package. In the UK, sometimes a Border Force letter, depending on the volume and the inspecting officer. In Canada, a CBSA notice is standard. In some EU countries, no letter at all if the package is simply destroyed at the border under intra-customs administrative procedures. The presence or absence of a letter does not change the underlying outcome — destruction is the routine result either way.

Can the FBI or DEA come to my house after a peptide seizure?

There are no documented cases of FBI or DEA enforcement against personal-use unscheduled research peptide buyers based on a single customs seizure. Federal-level home enforcement is reserved for trafficking-scale or controlled-substance cases. A Notice of FDA Action does not authorize a home search and does not constitute a referral to federal criminal investigators. The fear is widespread on Reddit and forums, but the documented pattern does not support it for personal-use unscheduled peptide imports.

Should I respond to the customs seizure notice or just ignore it?

For most personal-use research peptide seizures, doing nothing leads to administrative forfeiture and destruction with no further action. Filing a petition rarely succeeds for unapproved peptides and adds your name to a contested-claim record. Filing a claim triggers a federal civil lawsuit at significant cost. Most attorneys advising personal-use buyers recommend abandonment for ordinary research-peptide seizures — but this is general information, not legal advice for your specific situation. Consult a customs/administrative-law attorney if quantities are large, the compound carries its own criminal statute (HGH especially), or you have repeated seizures.

Will my future packages from any vendor be flagged after one seizure?

Address-level flagging exists in CBP's risk-targeting system but is not blanket surveillance. Repeat seizures from the same vendor are the strongest predictor of future intercepts; isolated single seizures rarely produce ongoing scrutiny. Buyers who switch vendors, change source country, and space out subsequent orders typically see baseline interception rates restored within 6–12 months. The flag is more vendor-pattern-specific than address-specific.

Can my vendor reship a seized order?

Some vendors guarantee free reship on customs seizure with proof of the seizure notice; others split the cost 50/50; others refuse. Reship policy is listed on the vendor's terms-of-service page. Confirming the policy before ordering is one of the cheapest seizure-risk hedges available to a buyer. Peptigrity's shop directory tracks reship policies where they have been verified, alongside the trust-score data.

Is BPC-157 specifically more likely to be seized than other peptides?

BPC-157 currently sits on the FDA's Category 2 list under the 503A interim policy, with a Cat 2-to-Cat 1 reclassification pending under the April 2026 Kennedy directive (the formal FDA list and the July 2026 PCAC review will determine the final status). It is unscheduled in most other jurisdictions. Customs seizure risk for BPC-157 is similar to other research peptides — packaging, vendor origin, and order size matter more than the specific compound. Verify the FDA Bulk Drug Substances list for current status before relying on this answer.

What about GLP-1s like semaglutide and tirzepatide — different rules?

Yes — GLP-1 receptor agonists such as semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), and retatrutide (investigational) are FDA-approved or in late-stage clinical trials, which means they are treated as prescription drugs rather than research chemicals. Importing them without a prescription is treated more strictly than importing unscheduled research peptides; counterfeit GLP-1s were among the most-seized categories in Operation Pangea XVII. Compounding pharmacy access via 503A may now be available for some of these compounds — see Peptigrity's compounding pharmacy vs research peptide article for current status. The destruction-only routine outcome described elsewhere in this article does not reliably extend to FDA-approved prescription drugs, including GLP-1s.

This article is for educational and informational purposes only and does not constitute legal advice. Customs and import laws vary by jurisdiction and change frequently — verify current regulations for your country before importing any compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors. If you have received a customs seizure notice and are unsure how to respond, consult a licensed customs or administrative-law attorney in your jurisdiction.